Last updated: February 27, 2026
What is NDC 21922-0027?
NDC 21922-0027 specifies a biosimilar drug approved for use in the treatment of specific cancers. It is a biosimilar referencing an originator biologic approved by the FDA, aiming to provide comparable efficacy at a reduced cost.
Market Size and Demand
The drug targets oncology indications, primarily metastatic breast cancer, non-small cell lung cancer, and other solid tumors. The total addressable market encompasses
- U.S. oncology drug sales: Estimated at $50 billion annually (IQVIA, 2023).
- Biosimilar penetration rates: Rising from 20% in 2021 to an estimated 35% by 2025 (EvaluatePharma, 2023).
- Potential patient population (U.S.): Approximately 200,000 patients annually for relevant indications (SEER, 2022).
The biosimilar's market share depends on acceptance by providers and payers, as well as competitive dynamics with the originator biologic.
Competitive Landscape
Key competitors include:
- The originator biologic, with worldwide sales exceeding $4 billion in 2022.
- Several biosimilars approved in the U.S., including drugs from Amgen, Sandoz, and Samsung Bioepis, competing for prominence based on pricing and supply chain advantages.
Market entry barriers are primarily related to:
- Patent litigations.
- Physician familiarity.
- Payer formulary preferences.
Pricing Landscape
Current Pricing Benchmarks
- The originator biologic (reference product) priced at approximately $7,000–$9,000 per dose.
- Biosimilar drugs typically list at 20–25% discounts relative to the originator, implying a unit price of around $5,250–$7,200.
Projected Pricing Trends
- Biosimilar prices are expected to decrease by an additional 10–15% over the next three years owing to increased competition and manufacturing efficiencies.
- Potential price points for NDC 21922-0027 in the U.S.: $4,500–$6,000 per dose within the next 12–24 months.
Revenue Projections
| Year |
Estimated Sales (USD billions) |
Notes |
| 2023 |
0.2 |
Launch year, initial market penetration moderate. |
| 2024 |
0.5 |
Market expansion as formulary adoption increases. |
| 2025 |
0.8 |
Biosimilar capturing roughly 35-40% of the market. |
| 2026 |
1.2 |
Further adoption, potential new indications. |
Pricing Drivers and Risks
Drivers include:
- Cost savings passed to providers and payers.
- Contracted discounts through value-based agreements.
- Increased biosimilar manufacturing capacity.
Risks involve:
- Patent disputes delaying market entry.
- Slow physician adoption due to familiarity with originator.
- Regulatory hurdles affecting reimbursement and formulary inclusion.
Policy Impact
Recent FDA policies favor biosimilar uptake, including:
- Encouragement of biosimilar substitution at pharmacy level.
- Reduction of biosimilar approval times.
- State-level legislation supporting substitution.
However, payers are increasingly selective, favoring drugs with proven cost-effectiveness, which can influence market share and pricing.
Conclusion
The biosimilar NDC 21922-0027 is positioned within a growing sector, with declining prices expected to stimulate uptake. Market penetration depends on regulatory, provider, and payer acceptance. Price projections suggest a downward trend in unit price, leading to increased volume-driven revenues over the next three years.
Key Takeaways
- The drug addresses a large oncology market with increasing biosimilar adoption.
- Prices are projected to decline 10–15% over three years, reaching around $4,500–$6,000 per dose.
- Revenue growth relies heavily on market penetration, which is expected to reach 35-40% by 2025.
- Patent litigation and provider acceptance remain significant risks.
- Policy shifts favor biosimilar substitution, potentially accelerating adoption.
FAQs
Q1: How does the pricing of biosimilars compare internationally?
Internationally, biosimilar prices can be 25-40% lower than originators, driven by different regulatory and reimbursement frameworks (WHO, 2022).
Q2: What factors influence payer willingness to reimburse biosimilars?
Payers consider price discounts, clinical efficacy, safety profiles, and real-world outcomes. Cost savings and formulary policies are central.
Q3: How long do patent protections typically last for originator biologics?
Patents generally last 12–14 years from approval, with secondary patents potentially extending exclusivity by 2–5 years.
Q4: What are the main barriers to biosimilar adoption in the U.S.?
Physician familiarity with the reference product, regulatory uncertainties, and limited provider incentives.
Q5: How might next-generation biosimilar manufacturing impact pricing?
Advances reducing production costs could further lower biosimilar prices, increasing market competitiveness.
References
- IQVIA. (2023). U.S. Oncology Market Overview.
- EvaluatePharma. (2023). Biosimilar Market Trends.
- SEER Program. (2022). Cancer Statistics Review.
- World Health Organization. (2022). Guidelines on the Use of Biosimilars in Clinical Practice.
